Mycoplasma pneumoniae and Chlamydia spp. Infection in Community-Acquired Pneumonia, Germany, 2011–2012

Roger Dumke, Christiane Schnee, Mathias W. Pletz, Jan Rupp, Enno Jacobs, Konrad Sachse, Gernot Rohde, CAPNETZ Study Group

Mycoplasma pneumoniae and Chlamydia spp., which are associated with community-acquired pneumonia (CAP), are difficult to propagate, and can cause clinically indistinguishable disease patterns. During 2011–2012, we used molecular methods to test adult patients in Germany with confirmed CAP for infection with these 2 pathogens. Overall, 12.3% (96/783) of samples were positive for M. pneumoniae and 3.9% (31/794) were positive for Chlamydia spp.; C. psittaci (2.1%) was detected more frequently than C. pneumoniae (1.4%). M. pneumoniae P1 type 1 predominated, and levels of macrolide resistance were low (3.1%). Quarterly rates of M. pneumoniae–positive samples ranged from 1.5% to 27.3%, showing a strong epidemic peak for these infections, but of Chlamydia spp. detection was consistent throughout the year. M. pneumoniae–positive patients were younger and more frequently female, had fewer co-occurring conditions, and experienced milder disease than did patients who tested negative. Clinicians should be aware of the epidemiology of these pathogens in CAP.

Community-acquired pneumonia (CAP) is associated with high rates of illness and hospitalization; annual CAP incidence among adults in Europe has ranged from 1.5 to 1.7 per 1,000 population (1). Studies have shown that a broad range of pathogens can cause CAP (2). Among these is Mycoplasma pneumoniae, a common agent of respiratory tract infections that is transmitted from person to person through aerosolization. The infection occurs in all age groups, but older children and young adults are affected at a higher frequency than other age groups. Clinical manifestations range from mild cases of tracheobronchitis to severe atypical pneumonia and can be followed by a broad spectrum of extrapulmonary complications.

The epidemiology of M. pneumoniae infection is characterized by incidence peaks every 4–7 years; during these periods, M. pneumoniae is responsible for up to 25% of all cases of CAP (3). Between epidemic periods, proportions of 1%–8% are more typical (4). Reports from Europe and Asia have shown a notable increase in the frequency of infections caused by M. pneumoniae during 2011–2012 (5–12).

For clarification of the epidemiology of M. pneumoniae infection and identification of the relevant periods of incidence peaks, molecular typing of the prevalent strains can be an efficient tool. M. pneumoniae strains can be divided into subtypes and variants according to sequence differences in the gene coding for the immunodominant main adhesin P1. It has been hypothesized that the specific antibody level in the host population can influence further infections and lead to a change of the dominating P1 type (13). The recently developed multilocus variable-number tandem-repeat (VNTR) analysis (MLVA) enables differentiation of strains with higher discriminatory power (14). Further studies are necessary to determine associations between P1 and MLVA typing. However, knowledge of the strain’s genotype identity currently has no therapeutic consequences. Because mycoplasmas, which do not have cell walls, are not susceptible to β-lactam antimicrobial drugs, macrolides are generally accepted as first-choice agents for treatment, especially in children. However, mutations in the 23S rRNA locus of M. pneumoniae have been shown to result in complete macrolide resistance (15). Resistance rates range from >90% in China (16) to <10% in Europe (15), requiring periodic monitoring of strains to identify possible new resistance or resistant strains.

Chlamydia pneumoniae is another agent associated with CAP that can also be involved in pharyngitis,
bronchitis, and sinusitis. Reports have attributed 6%–20% of CAP cases to this bacterium (17), and its role in chronic respiratory illness (18) and exacerbation of asthma (19) has also been studied. C. pneumoniae infection is regarded as widely distributed, if not ubiquitous, with antibody prevalence rates >50% (19). The clinical course of infection varies from subclinical to mild and, more rarely, to severe manifestations of pneumonia. The outcome of infection is often dependent on the patient’s immune competence, but co-infection by other bacteria has been suggested to be relevant in 30% of adult cases of CAP (20). However, a discrepancy exists between the elevated serologic prevalence and the low figures obtained through DNA-based detection methods (21); a recent publication from Germany reported a prevalence <1% (22).

Other Chlamydia spp. have not usually been included in epidemiologic studies of pneumonia. In particular, C. psittaci, the causative agent of human psittacosis (or ornithosis), has not been investigated except in severe clinical pneumonia cases. As is the case for infections caused by other chlamydiae, an asymptomatic or mild clinical course of C. psittaci is far more frequent than a fulminant outbreak of disease. Nevertheless, infections that do not result in overt illness may have long-term implications for the patient’s health, as was shown in cattle that were carriers of Chlamydia spp. but did not show signs of disease (23).

In this study, we used molecular diagnostic approaches to investigate the occurrence of M. pneumoniae and Chlamydia spp. in adult patients in Germany who had confirmed CAP. The use of molecular typing methods for M. pneumoniae in combination with the determination of macrolide resistance was intended to obtain a nationwide overview of circulating strains in a period of high incidence of infections. Parallel testing for Chlamydia spp. was included to explore the frequency of co-infections with 2 microorganisms that are difficult to propagate and that can cause disease patterns that may be clinically indistinguishable.

For this study, we prospectively recorded all consecutive and nonselected patients who sought treatment for signs and symptoms of CAP during March 2011–December 2012. Eligible participants were adult patients (>18 years of age) who had CAP confirmed by a new pulmonary infiltrate on chest radiograph and ≥1 sign or symptom of lower respiratory tract infection (i.e., fever, cough, purulent sputum, focal chest signs). Exclusion criteria were the following: hospital admission within 28 days before sampling, presence of immunosuppression (defined as chemotherapy and/or neutropenia <1,000 10⁶/L during the previous 28 days), therapy with corticosteroids >20 mg for >14 days, known HIV infection, immunosuppressive therapy after organ or bone marrow transplant, or active tuberculosis. All patients gave written informed consent and received a pseudonym from an independent third party to ensure data security. The study is registered at the German Clinical Trial Register (DRKS-ID: DRKS00005274).

All patients provided pharyngeal swab specimens for the determination of the presence of M. pneumoniae and Chlamydia spp. Follow-up consultations by phone call to patient or next of kin or family physician were conducted 28 days and 180 days after enrollment. All demographic, clinical, and diagnostic data for patients were recorded using standardized Web-based data sheets created by 2mt (Ulm, Germany). The study was approved by the Institutional Review Board of the Otto-von-Guericke University (Magdeburg, Germany) under ID 104/01 in 2001 and subsequently by all local institutional review boards.

Sample Processing and Microbiological Investigations

DNA Extraction
Swab specimens were shipped overnight in transport medium to the Friedrich-Loeffler-Institut (Jena, Germany) for testing. DNA extraction was performed by using the High Pure PCR Template Preparation Kit (Roche Diagnostics, Mannheim, Germany) according to the manufacturer’s instructions.

Testing for Chlamydia spp.
To test for Chlamydia spp., we first conducted a real-time PCR specific for the family Chlamydiaceae (25). Positive samples were further examined by using a C. psittaci–specific real-time PCR (26) and a DNA microarray assay in ArrayStrip format that covered all Chlamydia spp., Waddlia chondrophila, and Simkania negevensis (27,28).

Testing for M. pneumoniae
Aliquots of the DNA extracts were examined by using a previously described real-time PCR assay targeting copies of the repetitive element RepMP1 (29). Positive samples were further tested for macrolide resistance by methods
previously reported (15). P1 and MLVA type were determined by nested PCR approaches and sequencing (30,31).

Statistical Analysis
Categorical data are presented as frequencies and were compared by χ² or Fisher exact test, as appropriate. The Yates correction procedure was applied to all comparisons. Continuous variables are presented as median and range. Differences were analyzed by using the Mann-Whitney U test; p values <0.05 were considered significant. All analyses were carried out in SPSS version 20 software (IBM/SPSS, Chicago, IL, USA).

Results
Overall, 783 CAP patients were enrolled during March 2011–December 2012 and were tested for M. pneumoniae; 96 (12.3%) were positive. Patients who had M. pneumoniae infection were significantly younger and more frequently female; had fewer co-occurring conditions, and experienced significantly milder disease that did those who did not have M. pneumoniae infection (Table 1). M. pneumoniae–positive patients were more frequently pretreated with antimicrobial drugs; however, we found no significant differences in the classes of antimicrobial drugs administered, particularly not in the use of macrolides.

Using real-time PCR targeting the RepMP1 copies in the M. pneumoniae genome, we calculated a median of 7.8×10³ copies (range 4.1×10¹ to 1.5×10⁶) in the M. pneumoniae–positive samples. M. pneumoniae positivity showed a clear season-dependent trend; low positivity of ≈4% was found at the beginning and the end of the investigation period, but high positivity was found during October 2011–December 2011. Quarterly incidence ranged from 1.5% (quarter 3, 2012) to 27.3% (quarter 4, 2011) (Figure 1).

The percentage of M. pneumoniae–positive patients from each age group ranged from 28.1% for the 18- to 29-year age group to 13.5% for the ≥60-year age group (Figure 2). The prevalence of M. pneumoniae decreased by age group: 18–29 years, 38%; 30–39 years, 31%; 40–49 years, 17%; 50–59 years, 13%; ≥60 years, 3%. More than half (55%) of M. pneumoniae–positive patients were female; only the 18- to 29-year age group had more M. pneumoniae–positive men than women.

Regarding the P1 genotype, all strains in the 96 M. pneumoniae–positive samples could be typed culture independently. Subtype 1 strains dominated (60.4%; Figure 1, panel B), followed by variant 2a (19.8%), variant 2b (9.4%), variant 2c (8.3), and subtype 2 strains (2.1%). A high proportion of subtype 1 strains were found during the entire 22-month investigation period, and all P1 types detected during the period were found at nearly the same proportion during the high-incidence period of October–December 2011.

Highly discriminatory MLVA was carried out on all positive samples using nested PCR. For 87 of the 96 samples, the complete recommended panel of 5 tandem-repeat regions could be amplified and sequenced successfully. Overall, 23 MLVA types were identified. The most common MLVA types were 4/4/5/7/2 (n = 12, 13.8%) and 5/4/5/7/2 (n = 11, 12.6%). During the high-incidence period (quarter

Table 1. Demographic and clinical characteristics of patients with community-acquired pneumonia whose respiratory tract samples were tested for Mycoplasma pneumoniae, Germany, 2011–2012*

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>All, n = 783</th>
<th>M. pneumoniae–positive, n = 96</th>
<th>M. pneumoniae–negative, n = 687</th>
<th>p value†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median age, y (range)</td>
<td>61 (18–102)</td>
<td>39.5 (18–84)</td>
<td>64 (18–102)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Male sex</td>
<td>56.8</td>
<td>43.8</td>
<td>58.7</td>
<td>0.008</td>
</tr>
<tr>
<td>BMI (range)</td>
<td>25.6 (13.9–56.5)</td>
<td>24.2 (18.8–44.5)</td>
<td>25.8 (13.9–56.5)</td>
<td></td>
</tr>
<tr>
<td>Co-occurring conditions</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chronic pulmonary disease</td>
<td>19.2</td>
<td>6.2</td>
<td>23.1</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Chronic renal disease</td>
<td>19.2</td>
<td>0</td>
<td>20.6</td>
<td>0.004</td>
</tr>
<tr>
<td>Chronic heart failure</td>
<td>26.1</td>
<td>11.3</td>
<td>27.2</td>
<td></td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>24.9</td>
<td>11.1</td>
<td>25.9</td>
<td></td>
</tr>
<tr>
<td>Cerebro-vascular disease</td>
<td>9.5</td>
<td>3.7</td>
<td>9.3</td>
<td></td>
</tr>
<tr>
<td>CURB scores‡</td>
<td></td>
<td></td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>0</td>
<td>57.3</td>
<td>77.0</td>
<td>54.7</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>31.0</td>
<td>21.8</td>
<td>32.2</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>10.5</td>
<td>1.1</td>
<td>11.8</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>1.2</td>
<td>0</td>
<td>1.4</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Antimicrobial drug pretreatment</td>
<td>29.3</td>
<td>57.0</td>
<td>26.2</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Macrolides</td>
<td>8.0</td>
<td>7.3</td>
<td>8.3</td>
<td>$</td>
</tr>
<tr>
<td>Mortality rate</td>
<td>28 d</td>
<td>1.8</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>180 d</td>
<td>4.6</td>
<td>0</td>
<td>5.2</td>
</tr>
</tbody>
</table>

*Values are percentages except as indicated. BMI, body mass index.
†Only significant values are shown. Comparison between M. pneumoniae–positive and -negative patients by χ² or Mann-Whitney U test as appropriate.
‡Clinical evaluation of the following risk factors (each scores 1 point): Confusion; blood Urea >7 mmol/L; Respiratory rate ≥30 bpm; Blood pressure <90 (systolic) or ≤80 mm Hg (diastolic).
§Also no significant differences for any other antimicrobial drug classes.
4 of 2011), the 42 M. pneumoniae strains that showed valid MLVA results belonged to 16 MLVA types. No clear correlation was found between P1 and MLVA typing. The 51 classifiable subtype 1 strains can be assigned to 16 MLVA types (Table 2). Five of these MLVA types can also be found in subtype 2 and the related variant 2 strains.

On the basis of sequencing data, macrolide resistance can be assumed in 3 of the 96 M. pneumoniae–positive specimens (3.1%). All strains showed an A→G mutation at position 2063 of the 23S rRNA. The macrolide-resistant strains belonged to the predominant subtype 1 in P1 typing but differed in MLVA type (2/3/6/2/2, 2/4/5/7/2, and 5/4/5/7/2). The specimens containing resistant strains were sampled at different points of the study: December 2011, April 2012, and August 2012. All affected patients were female (ages 31, 42, and 42 years). For 2 of these patients, treatment with macrolides during the month before sampling was reported.

We further tested 794 patients for Chlamydia spp. (Table 3); 31 (3.9%) patients tested positive, 6 with dual infections (Table 4). In contrast to the M. pneumoniae findings, we found no significant differences in clinical characteristics between Chlamydia-positive and -negative patients (Table 3). Notably, no Chlamydia-positive patients received macrolides, whereas 8.3% of Chlamydia-negative patients did.

Test results identified C. psittaci (2.1%) as the most prevalent chlamydial species, followed by C. pneumoniae (1.4%). In addition, C. trachomatis, Simkania negevensis, and the animal pathogens C. suis, C. abortus and Waddlia chondrophila were identified in individual samples. The use of a DNA microarray assay combined with real-time PCR assays enabled us to detect multiple chlamydial infections; all 6 dual chlamydial infections (representing 19.3% of Chlamydia-positive patients) involved C. psittaci, 3 in conjunction with C. pneumoniae and 1 each with C. abortus, S. negevensis, and W. chondrophila. Co-infections with M. pneumoniae and Chlamydia spp. were detected in 3 samples (3.1% of M. pneumoniae–positive and 8.1% of Chlamydia-positive specimens): 1 M. pneumoniae + C. psittaci, 1 M. pneumoniae + C. pneumoniae, and 1 M. pneumoniae + C. psittaci + C. pneumoniae.

**Discussion**

Many studies have described the strictly time-dependent epidemiology of infections caused by M. pneumoniae (3). Although we did not include serologic testing to provide further information for the differentiation of colonization of patient from infection, the results of our study confirm a strong epidemic peak of M. pneumoniae–positive...
respiratory samples among adult patients with suspected CAP in Germany during 2011–2012. The incidence of infections temporarily rose to ≈27% during the fourth quarter of 2011, a level that is in accordance with other reports (5–12). Despite limited comparability (e.g., target used), the number of RepMP1 copies measured with real-time PCR (median 7.8 × 10^3) is in the range of results of other studies (5–12). Therefore, P1 genotyping of circulating strains from patients with community-acquired pneumonia whose respiratory tract samples were tested for *Chlamydia* spp., Germany, 2011–2012*

Table 3. Demographic and clinical characteristics of patients with community-acquired pneumonia whose respiratory tract samples were tested for *Chlamydia* spp., Germany, 2011–2012*"}

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>All, n = 794</th>
<th>Chlamydia-positive, n = 31</th>
<th>Chlamydia-negative, n = 763</th>
<th>p value†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median age, y (range)</td>
<td>61 (18–102)</td>
<td>64 (18–89)</td>
<td>61 (18–102)</td>
<td></td>
</tr>
<tr>
<td>Male sex</td>
<td>56.8</td>
<td>54.8</td>
<td>56.9</td>
<td></td>
</tr>
<tr>
<td>BMI (range)</td>
<td>25.6 (13.9–56.5)</td>
<td>24.3 (17.7–45.3)</td>
<td>25.7 (13.9–56.5)</td>
<td></td>
</tr>
<tr>
<td>Co-occurring</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chronic pulmonary disease</td>
<td>21.2</td>
<td>32.3</td>
<td>20.7</td>
<td></td>
</tr>
<tr>
<td>Chronic renal disease</td>
<td>19.2</td>
<td>0</td>
<td>19.9</td>
<td>p = 0.05</td>
</tr>
<tr>
<td>Chronic heart failure</td>
<td>25.7</td>
<td>12.5</td>
<td>26.2</td>
<td></td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>24.8</td>
<td>25.0</td>
<td>24.8</td>
<td></td>
</tr>
<tr>
<td>Cerebro-vascular disease</td>
<td>9.3</td>
<td>12.5</td>
<td>9.2</td>
<td></td>
</tr>
<tr>
<td>CURB scores‡</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>56.8</td>
<td>54.8</td>
<td>56.9</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>31.5</td>
<td>41.9</td>
<td>31.0</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>10.5</td>
<td>3.2</td>
<td>10.8</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>1.2</td>
<td>0</td>
<td>1.2</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Antimicrobial drug pretreatment</td>
<td>29.1</td>
<td>25.8</td>
<td>29.3</td>
<td></td>
</tr>
<tr>
<td>Macrolides</td>
<td>7.9</td>
<td>0</td>
<td>8.3</td>
<td>§</td>
</tr>
<tr>
<td>Mortality rate</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>28 d</td>
<td>1.8</td>
<td>6.5</td>
<td>1.6</td>
<td></td>
</tr>
<tr>
<td>180 d</td>
<td>4.7</td>
<td>6.5</td>
<td>4.6</td>
<td></td>
</tr>
</tbody>
</table>

*Values are percentages except as indicated. BMI, body mass index.
†Only significant values are shown. Comparison between Chlamydia-positive and -negative patients by χ² or Mann-Whitney U test as appropriate.
‡Clinical evaluation of the following risk factors (each scores 1 point): Confusion; blood Urea > 7 mmol/L; Respiratory rate ≥ 30 bpm; Blood pressure < 90 (systolic) or ≤ 60 mm Hg (diastolic).
§Also no significant differences for other antibiotic classes.
In this study, only particular regions of the P1 gene were selected for analysis, and the occurrence of additional P1 types showing further sequence variations cannot be ruled out. The recently characterized variant 2d (35) shares an identical 3’ part of the RepMP2/3 with variant 2a but differs in the 5’ region of the repetitive element; on the basis of those results, we retested all variant 2a strains, but we could not confirm the occurrence of variant 2d.

For epidemiologic reasons, it is important that the period with a high proportion of M. pneumoniae–positive samples (October–December 2011) was not associated with a change of the dominating genotype nor with the presence of a particular P1 type. Previous reports have hypothesized that the circulation of genotype-specific antibodies in the human population can influence the number of infections and the dominating P1 type (13), but our data do not support this hypothesis.

In recent years, MLVA was introduced for typing of M. pneumoniae isolates (14) and extended to culture-independent typing from clinical samples (31). The determination of the number of 5 VNTR markers (Mpn1, 13–16) enables characterization of strains with a higher discriminatory power in comparison with P1 typing. Whereas the genomic regions used for MLVA are located mainly between genes and within genes of unknown function, the P1 protein plays a critical role in host–pathogen interaction. The most common MLVA types (4/4/5/7/2 and 5/4/5/7/2) we detected were also found in high abundance in strains recently identified in France, China, and the United States (11,16,36), thus indicating a worldwide dissemination of particular MLVA types.

Regarding the strains included in our study, the assignment of P1 types to MLVA types confirmed that no clear relationship between the typing methods exists (Table 2). In agreement with the results of other reports (11,14,16), a low number of P1 subtype 1 strains belong to MLVA types that are typical for subtype 2 or variant strains (e.g., 5/3/5/6/2) and vice versa. In our opinion, both typing approaches are of practical importance and complement each other; the circulating P1 types reflect a more host-dependent pattern, whereas MLVA can differentiate strains with higher discriminatory power, enabling a better understanding of epidemiologic relationships.

Instability of VNTR marker 1 has been reported (36), and the removal of Mpn1 from the current MLVA scheme has been suggested (16). For our data, the removal of Mpn1 would reduce the number of MLVA genotypes to 9, with >80% of strains belonging to 2 types, 3/5/6/2 and 4/5/7/2. This change would result in a substantial decrease of the discriminatory power of the MLVA typing method and would require efforts to include further VNTR markers showing a stable number of repeats within a given strain.

The data from our study confirm that a nationwide peak of infections caused by M. pneumoniae is polyclonal, which is in agreement with results of other reports (11). In contrast, the clonal spread of M. pneumoniae can only be expected for small-scale endemic outbreaks with person-to-person transmission in close communities, such as families (37).

Since 2000, an increase of the worldwide occurrence of macrolide resistance in M. pneumoniae strains to 90% and higher has reported. Compared with data from Asia (16), the proportion of 3.1% of macrolide-resistant M. pneumoniae strains we detected is low. Results of studies from Germany in recent years have showed results in the same range (15), thus indicating a nearly constant prevalence of resistance. Nevertheless, resistant strains are circulating in the population we investigated, which requires further monitoring of strains to provide an updated overview of drug resistance. Several reports have confirmed that resistant strains were selected during antimicrobial drug treatment (38). However, in our study, increased prescription of macrolide antimicrobial drugs, which can be expected during a period of high CAP incidence, did not result in a measurable increase of resistant strains. In addition, because most current resistance data originate from pediatric patients, the results of this study are of general interest because we report on adult patients.

Although further sequence differences of the 23S rRNA locus of M. pneumoniae have been described, the A→G mutation at position 2063 is most common (15,16). Comparison of sequencing results with antimicrobial susceptibility testing confirmed that the mutation at positions 2063/2064 led to a high level of macrolide resistance (15). Thus, with the mutation detected, resistance of these strains can be assumed. We did not find macrolide resistance to be associated with a certain MLVA type, which confirms the findings of other reports (16), but the low number of resistant strains in our study is insufficient for us to draw a final conclusion.

The results of Chlamydia testing are remarkable for the comprehensive methodologic approach. In the past, the choice of diagnostic tests was usually limited: that is, either
only *C. pneumoniae* was analyzed or all *Chlamydia* spp. identified were thought to be *C. pneumoniae*. Although the positivity of 1.4% for *C. pneumoniae* we found is in line with previous data from Germany (22), the proportions of positive samples of 2.1% for *C. psittaci* and 4.7% for all *Chlamydia* spp. considered here deserve specific attention (Table 4). Chlamydial co-infection involving ≥2 *Chlamydia* spp. has been shown to be frequent in trachoma patients (39), but data from pneumonia patients remain scarce. Our finding that 19.3% of *Chlamydia*-positive patients harbored ≥2 *Chlamydia* spp. is in the same range as the 24% found in a recent trachoma study (40).

One unexpected finding in our study was that *C. psittaci* positivity could not be correlated with the patients having regular contact with birds at home or at work. Moreover, no seasonal patterns were identified. Nevertheless, our findings indicate that chlamydial species other than *C. pneumoniae* should be included in testing of CAP patients; in particular, *C. psittaci* should be included but also *C. trachomatis*. The relatively high prevalence of *C. psittaci* we found raises questions about its epidemiologic and etiologic importance, which should be addressed in future studies.

In summary, we confirmed a strong epidemic peak of *M. pneumoniae*–positive respiratory samples among adult patients with confirmed CAP in Germany during 2011–2012. During the fourth quarter of 2011, the incidence of infections temporarily rose to ≈27% of all patients investigated. *Chlamydia* spp. were found in 3.9% of samples, without epidemic peaks. Throughout the study period, the dominant *M. pneumoniae* P1 type was subtype 1; only 3.1% of *M. pneumoniae* strains were macrolide resistant. Both bacteria represent relevant pathogens in CAP, and awareness of their epidemiology, particularly among clinicians, is clearly warranted.

Members of the CAPNETZ Study Group: M. Dreher, C. Cornelissen (Medical Clinic I, University Clinic RWTH Aachen, Aachen, Germany); W. Knüppel, I. Armari (Clinic for Internal Medicine, Hospital Bad Arolsen, Bad Arolsen, Germany); D. Stolz (Clinic for Pneumology, Uni-Spital, Basel, Switzerland); N. Suttrop, H. Schütte, P. Creutz (Department of Infectious Disease and Respiratory Medicine, Charité-University Medicine, Berlin, Germany); T. Bauer, T. Weiß (HELios Klinikum Emil von Behring, Berlin); W. Pankow, A. Lies, D. Thiemig (Clinic for Internal Medicine, Pneumology and Infectiologist, Vivantes Clinical Center, Berlin-Neukölln, Germany); B. Hauptmeier, D. Wehde, M. Suermann (University Hospital Bergmannsheil, Department of Pneumology, Allergology and Sleep Medicine, Bochum, Germany); S. Ewig (Department of Respiratory Medicine and Infectious Diseases, Augusta Hospital, Bochum); M. Prediger, G. Zemia (III Medical Clinic, Carl-Thiem-Klinikum Cottbus); G. Höflken, M. Kolditz (Medical Clinic I, Pneumology, University Clinic Dresden, Germany); T. Welte (Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany); G. Barten, M. Abrahmczik, J. Naim, W. Kröner (Main Office, Hannover); T. Illig, N. Klopp (Hannover Unified Biobank); C. Kroege (Department of Cardiology, Angiology, Pneumology, Internal Intensive Care Medicine, University Hospital Jena, Germany); M. Pletz (Centre for Infection Medicine and Hospital Hygiene [ZIMK], University Hospital, Jena); K. Dalhoff, S. Schütz, R. Hörster (Med. Clinic III, Pulmonology, University Clinic Schleswig-Holstein, Lübeck, Germany); G. Rohde (Department of Respiratory Medicine, Maastricht University Medical Center, MUMC+; Maastricht, the Netherlands); H. Buschmann, R. Kröning (Brüderkrankenhaus St. Josef, Medical Clinic, Pneumology, Paderborn, Germany); T. Schaberg, I. Hering (Center of Pneumology, Diakonie-Hospital, Rotenburg, Germany); C. Schumann (Department of Internal Medicine II, University of Ulm, Ulm, Germany); T. Illmann, M. Wallner (2mt Software, Ulm); and all study nurses.

Acknowledgments

We gratefully acknowledge the excellent technical assistance of Simone Bettermann, Sigrid Gähler, Joëlle Naim, and Christine Grajetzki. We express our appreciation to all clinical physicians and physicians in private practice who saw and identified patients with community-acquired pneumonia for their work dedicated to CAPNETZ. We thank the CAPNETZ study team either temporarily or permanently involved in patient recruitment, sample, and data handling, as well as the patients included in the CAPNETZ study; without their collaboration, this article would not have been written.

CAPNETZ is a multidisciplinary approach to better understand and treat patients with community-acquired pneumonia. The network is funded by the German Ministry of Education and Research (Bundesministerium für Bildung und Forschung), grant no. 01KJ07145. This study was financially supported by the Federal Ministry of Education and Research (BMBF) of Germany under grant no. 01KJ07145 “CAPNETZ” and 01 KI 0720 “Zoonotic chlamydiae—Models of chronic and persistent infections in humans and animals.” The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Dr. Dumke is a microbiologist at the Institute of Medical Microbiology and Hygiene, Technical University Dresden, Dresden, Germany. His research interests focus on detection of *M. pneumoniae* infections and characterization of *M. pneumoniae* strains.

References

Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 21, No. 3, March 2015


Address for correspondence: Gernot Rohde, Maastricht University Medical Center Department of Respiratory Medicine, PO Box 5800, 6202 AZ Maastricht, P. Debyeplein 25, 6229 HX Maastricht, the Netherlands; email: g.rohde@mumc.nl

Recognize the signs of tickborne disease
Understand diagnostic testing and lab findings
Quickly find treatment recommendations
Order or download at www.cdc.gov/pubs